“`html
Perspective Therapeutics, Inc. announced two presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting, taking place from June 21-24, 2025, in New Orleans, Louisiana. The first presentation focuses on the dosimetry of [212Pb]VMT-α-NET targeting advanced SSTR2-positive tumors, emphasizing safety and feasibility as an imaging surrogate for clinical trials. The second presentation details the preclinical evaluation and first human case of [68Ga]Ga-PSV377, showing promising results in PET imaging for multiple cancers.
The dosimetry study indicates the treatment’s safety profile, demonstrating feasibility for future clinical applications. Meanwhile, [68Ga]Ga-PSV377 exhibited high tumor retention in preclinical models, indicating its potential for effective cancer imaging. These advancements underline Perspective Therapeutics’ commitment to using alpha-emitting isotope 212Pb in personalized cancer treatments.
The presentations aim to strengthen the company’s position in the radiopharmaceutical market amidst ongoing trials that may raise investor scrutiny regarding efficacy outcomes.
“`
